I guess I am just dumber than a stump. The following paragraph from the article indicates a three month survival benefit for taking a drug that has a serious impact on quality of life and at some cost I am sure. What am I missing that would have the medical community cheering for what appears to be a negligible benefit? (at least to me) ( I understand averages... like the old joke. A man has his feet in a fire and his head in a freezer but is quite comfortable on the average.)
"At least 50% of the patients who use the drug will get a remission of some duration. In the studies, the men who received Taxotere-based therapy lived, on average, about three months longer when compared to men who received the old drug combination of prednisone (a corticosteroid) and the cancer medication Novantrone (mitoxantrone), which was approved by the FDA in 1996 as a treatment for the pain of metastatic prostate cancer."